1. Home
  2. CSWC vs SYRE Comparison

CSWC vs SYRE Comparison

Compare CSWC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSWC
  • SYRE
  • Stock Information
  • Founded
  • CSWC 1961
  • SYRE 2013
  • Country
  • CSWC United States
  • SYRE United States
  • Employees
  • CSWC N/A
  • SYRE N/A
  • Industry
  • CSWC Textiles
  • SYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CSWC Consumer Discretionary
  • SYRE Health Care
  • Exchange
  • CSWC Nasdaq
  • SYRE Nasdaq
  • Market Cap
  • CSWC 1.3B
  • SYRE 1.1B
  • IPO Year
  • CSWC N/A
  • SYRE 2016
  • Fundamental
  • Price
  • CSWC $22.80
  • SYRE $16.63
  • Analyst Decision
  • CSWC Buy
  • SYRE Buy
  • Analyst Count
  • CSWC 4
  • SYRE 5
  • Target Price
  • CSWC $24.13
  • SYRE $55.00
  • AVG Volume (30 Days)
  • CSWC 611.3K
  • SYRE 441.2K
  • Earning Date
  • CSWC 10-27-2025
  • SYRE 08-05-2025
  • Dividend Yield
  • CSWC 11.19%
  • SYRE N/A
  • EPS Growth
  • CSWC N/A
  • SYRE N/A
  • EPS
  • CSWC 1.64
  • SYRE N/A
  • Revenue
  • CSWC $209,032,000.00
  • SYRE N/A
  • Revenue This Year
  • CSWC $14.15
  • SYRE N/A
  • Revenue Next Year
  • CSWC $10.11
  • SYRE N/A
  • P/E Ratio
  • CSWC $13.91
  • SYRE N/A
  • Revenue Growth
  • CSWC 10.52
  • SYRE N/A
  • 52 Week Low
  • CSWC $17.46
  • SYRE $10.91
  • 52 Week High
  • CSWC $25.90
  • SYRE $40.26
  • Technical
  • Relative Strength Index (RSI)
  • CSWC 53.65
  • SYRE 50.48
  • Support Level
  • CSWC $22.29
  • SYRE $16.38
  • Resistance Level
  • CSWC $23.04
  • SYRE $17.39
  • Average True Range (ATR)
  • CSWC 0.28
  • SYRE 0.81
  • MACD
  • CSWC 0.02
  • SYRE -0.01
  • Stochastic Oscillator
  • CSWC 69.62
  • SYRE 43.48

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: